Advertisement

Topics

EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk

13:06 EDT 17 May 2019 | Medscape

The EMA's safety committee advises physicians not to prescribe the 10-mg twice-daily dose of tofacitinib to patients who are at high risk for pulmonary embolism, pending results of an ongoing safety review.
News Alerts

Original Article: EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk

NEXT ARTICLE

More From BioPortfolio on "EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk"

Advertisement
Quick Search
Advertisement
Advertisement